Semax Dosing Guide 2026: Protocols, Cycles, and What the Research Shows

Semax is a heptapeptide analogue of the adrenocorticotropic hormone (ACTH) fragment 4–7, developed at the Institute of Molecular Genetics in Moscow during the 1980s and 1990s. Its design goal was to isolate and amplify the neuroprotective and cognitive-enhancing properties of the parent ACTH sequence while eliminating its adrenocortical hormone effects. More than three decades of Russian clinical research have positioned it as one of the most studied neuropeptides for cognitive support, neuroprotection, and anxiety modulation.

This guide examines the administration routes, dosing ranges, cycle structures, and research evidence that underpin Semax protocols in 2026, including how it compares to its anxiolytic sibling Selank.

What Is Semax?

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic 7-amino-acid peptide based on the ACTH(4–7) sequence with a C-terminal proline-glycine-proline extension that enhances its metabolic stability. Unlike full ACTH, it has no effect on cortisol synthesis or adrenocortical function, making it a clean neuropeptide tool. It is available as Semax nasal drops and lyophilised powder for research use.

Mechanism of Action

Semax exerts its effects through several interconnected pathways:

• BDNF upregulation: Semax reliably increases brain-derived neurotrophic factor (BDNF) expression in the hippocampus and frontal cortex — the primary mediator of its neuroplasticity and memory-enhancing effects.
• Dopaminergic and serotonergic modulation: It elevates dopamine and serotonin turnover in prefrontal regions, contributing to improved attention, motivation, and mood.
• Anti-inflammatory neuroprotection: Semax reduces neuroinflammatory cytokine expression and oxidative stress, providing protection in ischaemia models and during neurodegeneration.
• Melanocortin receptor activity: Binding to MC4R in the CNS mediates some of its anxiolytic and mood-stabilising properties.

Intranasal vs Subcutaneous Administration

Semax is most commonly administered intranasally, as it bypasses the blood-brain barrier via the olfactory epithelium and trigeminal nerve pathways. Intranasal delivery achieves rapid CNS uptake without systemic injection. Subcutaneous administration is used in protocols where precise dosing and injectable delivery are preferred — plasma exposure is reliable but brain penetration relies on systemic transport.

Intranasal dosing ranges: 200–900 mcg per session (200–300 mcg for maintenance/low-dose, 600–900 mcg for neuroprotective or intensive protocols). Subcutaneous dosing ranges: 100–300 mcg per injection, once or twice daily.

Cycle Protocols

The standard Semax research cycle is 2–4 weeks of daily administration followed by an equal rest period. Shorter cycles of 10–14 days are used for acute cognitive enhancement or stress-resilience applications. Longer runs of 4–6 weeks have been used in stroke recovery and neuroprotection protocols in Russian clinical practice, though independent replication is limited. The rest interval prevents receptor desensitisation and maintains responsiveness.

Stacking with Selank

A popular research combination pairs Semax (pro-cognitive, dopaminergic) with Selank (anxiolytic, GABAergic). Semax provides cognitive drive and focus enhancement; Selank modulates anxiety and stabilises mood. Together they cover complementary neurological domains without mechanistic overlap. The combination is used in protocols targeting anxiety-driven cognitive impairment or high-stress performance contexts.

Side Effects and Tolerability

Semax has a well-documented low adverse-effect profile in available studies. Intranasal administration may cause mild nasal irritation or transient mucous membrane sensitisation with repeated use. Some subjects report mild stimulatory effects (increased alertness, reduced sleep onset) with evening dosing — morning administration is recommended to avoid this. No significant effects on cortisol, blood pressure, or metabolic parameters have been observed at research doses.

Frequently Asked Questions

What is the best time of day to use Semax?

Morning administration (upon waking, before food) is preferred for cognitive enhancement protocols. Evening dosing may delay sleep onset due to its mild stimulatory dopaminergic activity.

How many cycles of Semax can be run per year?

Standard research practice supports 3–4 cycles per year, each separated by rest periods of equal length. More frequent cycling is used in some Russian clinical settings but lacks robust independent safety data.

Does Semax increase cortisol?

No. The ACTH(4–7) fragment does not activate adrenocortical receptors responsible for cortisol synthesis. This is a key design feature distinguishing Semax from full ACTH and its longer analogues.

Is Semax suitable for long-term neuroprotection research?

Russian clinical use in stroke rehabilitation and Alzheimer's-related cognitive decline includes longer-term administration under medical supervision. For research purposes, cyclical use with monitoring of cognitive endpoints is the standard approach.

References

• Dolotov OV, et al. (2006). Semax, an analogue of ACTH4–10 with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54–60.
• Miasoedov NF, et al. (1999). Neuroprotective and nootropic properties of Semax. Biochemistry (Moscow), 64(Suppl 1), 1–12.
• Eremin KO, et al. (2005). ACTH4–10 affects monoaminergic and opioidergic systems. Neurochemical Research, 30(4), 519–525.
• Inozemtseva LS, et al. (2008). Intranasal administration of the peptide Semax regulates ACTH-receptor and glucocorticoid receptor gene expression. Doklady Biological Sciences, 421, 241–243.